Tryton Medical is a technology company.
Tryton Medical has raised $64.0M across 3 funding rounds.
Tryton Medical has raised $64.0M in total across 3 funding rounds.
Tryton Medical is a medical technology company specializing in cardiovascular devices, primarily developing the Tryton Side Branch Stent for treating coronary bifurcation lesions—points where arteries branch, often challenging in interventional cardiology.[1][2][4][7] The stent serves cardiologists and healthcare providers managing patients with complex coronary artery disease, solving the problem of incomplete coverage and suboptimal outcomes in side branch treatment by providing a dedicated, deployable solution alongside conventional main vessel stents.[1][2][4][5][7] Founded in 2003 and based in Durham, North Carolina, the company has raised $87M total, reaching Series G stage, with its FDA-approved device marking U.S. commercial launch around 2021 after global use in over 12,000 patients.[1][2]
Tryton Medical was founded in 2003 by Aaron V. Kaplan, M.D., a professor of medicine at the Geisel School of Medicine/Dartmouth-Hitchcock Medical Center, who identified the need for specialized stents to definitively treat bifurcation lesions in coronary arteries.[2] The idea emerged from gaps in existing cardiology interventions, where standard stents inadequately addressed side branches, prompting development of proprietary technology.[1][2][4] Early traction built through European, Middle East, and Africa commercialization, culminating in U.S. FDA approval as the only dedicated bifurcated stent and the first U.S. commercial case at New York-Presbyterian Hospital/Columbia University Medical Center.[2][7]
Tryton rides the trend of advancing interventional cardiology for complex coronary disease, where bifurcations account for 15-20% of lesions but historically yield higher complication rates with generic stents.[1][2] Timing aligns with rising percutaneous coronary interventions amid aging populations and diabetes-driven atherosclerosis, bolstered by FDA approval enabling U.S. market access post-global validation.[1][2][7] Market forces like demand for precise, outcome-predictable devices favor Tryton, influencing the ecosystem by setting a standard for bifurcation-specific tech and potentially expanding to peripherals or imaging integrations.[1][3][5]
Tryton is poised for U.S. market penetration with its独占 FDA-approved bifurcation stent, potentially accelerating revenue after $4M raised eight years ago.[1] Trends like AI-guided imaging and bioresorbable materials could enhance its Tri-ZONE platform, while partnerships with majors like Boston Scientific (evident in ecosystem ties) may drive scale.[1][2] Its influence may evolve from niche innovator to bifurcation treatment leader, simplifying procedures and improving patient outcomes in a $7B+ coronary stent market—reinforcing its role as the go-to for these high-risk anatomies.[1][7]
Tryton Medical has raised $64.0M in total across 3 funding rounds.
Tryton Medical's investors include RiverVest.
Tryton Medical has raised $64.0M across 3 funding rounds. Most recently, it raised $20.0M Venture Round in September 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2014 | $20.0M Venture Round | RiverVest | |
| Jan 1, 2013 | $24.0M Venture Round | RiverVest | |
| Sep 1, 2010 | $20.0M Series D | RiverVest |